Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data RedHill Biopharma Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0
0.1
4.01
8.36
6.29
64.4
85.8
61.8
6.53
8.04
Cost of revenue
2.13
2.84
2.26
36.9
49.4
33.3
3.46
3.19
Gross profit
0
0.1
1.88
5.52
4.03
27.5
36.4
28.5
3.07
4.85
Research and development
17.8
25.2
33
24.9
17.4
16.5
29.5
7.28
3.53
1.59
Selling, general and administrative
2.75
3.85
8.03
7.51
11.5
25.4
32.4
28.6
16.2
9.57
Operating income
-22
-30.5
-52
-39.3
-43.2
-63.7
-81.1
-42.8
12.6
-14.6
Interest expense
0.21
0.38
0.08
0.17
0.44
12.8
16.7
42.4
9.61
2.06
Interest income
1.12
1.55
6.51
0.68
1.34
0.27
0.05
13.6
20.9
8.4
Net income
-21.1
-29.4
-45.5
-38.8
-42.3
-76.2
-97.7
-71.7
23.9
-8.27
EPS, basic
-0.19
-0.23
-0.26
-0.17
-0.14
-0.21
-0.21
-0.12
0.01
0.00
EPS, diluted
-0.19
-0.24
-0.26
-0.17
-0.14
-0.21
-0.21
-0.12
0.01
0.00
Balance sheet
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
21.5
53.8
16.5
29
29
29.3
29.5
20
5.57
4.62
Receivables
0.1
1.53
0.96
1.22
28.7
31.7
34.5
2.59
2.54
Inventory
0.65
0.77
1.88
6.53
14.8
11
4.39
3.65
Total current assets
67.8
51.7
56.8
53.2
70.5
89.2
85.9
16.1
11.9
Property, plant and equipment
0.17
0.23
0.16
0.23
0.51
0.57
0.5
0.19
0.14
Lease right-of-use assets
3.58
5.19
3.65
6.69
0.99
0.3
Intangible assets
6.1
5.29
5.32
16.9
87.9
71.6
65.6
5.58
5.55
Total assets
74.2
57.3
62.4
74.1
180
181
159
23
18
Accounts payable
0.06
4.81
3.32
4.18
11.6
11.7
4.23
3.28
1.17
Short-term debt
115
Total current liabilities
5.36
11.8
10.4
10.6
73.2
81.5
197
20
22.2
Lease liabilities
2.98
3.81
2.57
6.44
0.46
0
Total liabilities
11.5
12.3
11.2
14.1
166
172
207
21
22.7
Paid-in capital
151
177
220
267
293
375
383
388
Retained earnings
-89.6
-133
-169
-208
-280
-368
-434
-408
-415
Total equity
60.1
62.7
45.1
51.2
60
13.9
8.88
-48.4
2.07
-4.68
Total liabilities and equity
74.2
57.3
62.4
74.1
180
181
159
23
18
Cash flow statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-21.1
-29.4
-45.5
-38.8
-42.3
-76.2
-97.7
-71.7
23.9
-8.27
Cash from operations
-17.8
-28.3
-44.8
-34.5
-40.7
-48.6
-65
-29.2
-35.8
-9.37
Capital expenditures
-0.01
-0.09
-0.15
-0.02
-0.17
-0.41
-0.12
-0.2
-0.01
-0.01
Cash from investing
-21.2
24.5
-18.6
5.35
5.16
-35.6
-8.14
8.3
0
-0.01
Stock issued
54.7
35.8
22.2
41.9
36.3
Cash from financing
54.8
36
25.7
41.8
35.5
84.4
73.5
11.5
21.4
8.42
Exchange rate effect
-0.15
0.04
0.37
-0.1
0.09
0.13
-0.1
-0.08
-0.02
0.01
Free cash flow
-17.8
-28.3
-44.9
-34.5
-40.9
-49
-65.2
-29.4
-35.8
-9.38
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $0.50 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
60.3%
Gross profit / revenue.
Operating margin
-181.7%
Operating income / revenue.
Net margin
-102.8%
Net income / revenue.
FCF margin
-116.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-116.5%
Cash from operations / revenue.
Return on assets (ROA)
-40.2%
Net income / average total assets.
R&D / revenue
19.7%
Research and development expense / revenue.
SG&A / revenue
118.9%
Selling, general and administrative expense / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
23.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-54.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
5.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
58.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-48.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
3.8%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y
-215.7%
Operating income vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-134.6%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-100.0%
EPS vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-21.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-53.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-24.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.54x
Current assets / current liabilities.
Quick ratio
0.32x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.21x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
126.0%
Total liabilities / total assets.
Interest coverage
-7.11x
Operating income / interest expense.
Working capital
-$10.3M
Current assets - current liabilities.
Goodwill and intangibles / assets
30.7%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.39x
Revenue / average total assets.
Fixed asset turnover
49.0x
Revenue / average property, plant and equipment.
Inventory turnover
0.79x
Cost of revenue / average inventory.
Days inventory
460 days
365 x average inventory / cost of revenue.
Receivables turnover
3.14x
Revenue / average receivables.
Days sales outstanding
116 days
365 x average receivables / revenue.
Days payables
254 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
322 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.00
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$0.00
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$3.0M
Share price x shares outstanding.
Enterprise value
-$1.6M
Market cap + total debt - cash - short-term investments.
P/S
0.38x
Market cap / revenue.
FCF yield
-308.4%
Free cash flow / market cap.
Earnings yield
-271.9%
Net income / market cap (the inverse of P/E).
What was RedHill Biopharma Ltd.'s revenue in fiscal 2024?
RedHill Biopharma Ltd. reported revenue of $8.0M for fiscal 2024, 23.2% higher than the year before.
Was RedHill Biopharma Ltd. profitable in fiscal 2024?
No. It reported a net loss of $8.3M.
How much free cash flow did RedHill Biopharma Ltd. generate in fiscal 2024?
Cash from operations of $9.4M minus capital expenditures of $9.0K left free cash flow of -$9.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.